You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

Interim Dividend Timetable - Revised Record Date

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that in light of the announcement earlier today regarding the proposed acquisition of the Healthcare Products Business from Sinclair IS Pharma plc (the "Acquisition"), and the associated vendor placing, the Company is deferring the record date for its Interim Dividend to 29 December 2015 (from 18 December 2015). The payment date remains 14 January 2016, as announced in the Company's interim results on 9 September 2015.

This change accommodates any unexpected delay in completion of the Acquisition up to the long stop date of 28 December 2015 and ensures that placees receive the interim dividend to which they are entitled.

For further information:

Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer

Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.